---
title: "Retatrutide vs tirzepatide: the third receptor and weight loss"
description: "Retatrutide vs tirzepatide compared: receptor targets, glucagon agonism, structure and molecular weight."
published: 2026-10-27
updated: 2026-10-27
canonical: https://vyraxlabs.co.uk/guides/retatrutide-vs-tirzepatide
research_use_only: false
---

# Retatrutide vs tirzepatide: the third receptor and weight loss

Retatrutide vs tirzepatide compared: receptor targets, glucagon agonism, structure and molecular weight.

Retatrutide and tirzepatide are both engineered incretin peptides built on a GIP backbone with a fatty diacid for half-life extension. The difference that matters in the literature is one receptor: tirzepatide activates GIP and GLP-1, while retatrutide adds glucagon receptor agonism on top of both. That single addition is the whole reason the pair is studied side by side.

|  | Tirzepatide | Retatrutide |
| --- | --- | --- |
| Receptor targets | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| Class | Dual agonist | Triple agonist |
| Length | 39 amino acids | 39 amino acids |
| Backbone | GIP | GIP |
| Half-life extension | C20 fatty diacid | C20 fatty diacid |
| Approx. molecular weight | 4,813 Da | 4,731 Da |
| Main research use | Combined incretin signalling | Glucagon contribution to energy balance |

## Why glucagon is the interesting part

Glucagon receptor activation raises energy expenditure and drives hepatic lipid handling, which is a different lever from incretin signalling. Adding it to a dual agonist gives a compound that acts on three pathways at once, and it makes retatrutide the tool of choice when a study is asking what glucagon receptor agonism contributes beyond GIP and GLP-1. Tirzepatide cannot answer that question on its own, because it has no glucagon activity.

## What the two have in common

Both are 39 amino acids long, both are built on a GIP backbone, both carry a C20 fatty diacid for albumin binding, and both are supplied as lyophilised powder. In a laboratory they are handled the same way and stored the same way. The similarity is why they work as a controlled pair: the backbone and the half-life chemistry are held constant, so the observed difference can be attributed to the receptor profile rather than to the scaffold.

## Identity checks matter more here

Because the two molecules are close in size and share a backbone, a mix-up between them is plausible and hard to see. The molecular weights differ by about 82 Da, which mass spectrometry resolves easily but the eye cannot. If you are running a comparative study, confirm the reported mass on the certificate for each batch against 4,813 Da for tirzepatide and 4,731 Da for retatrutide before you start.

## Choosing between them

- Studying combined incretin effects without glucagon: tirzepatide
- Studying the glucagon receptor contribution: retatrutide, with tirzepatide as the dual agonist control
- Separating GLP-1 receptor effects from everything else: semaglutide as the selective comparator
- Running all three in one model: keep the same batch and the same reconstitution protocol across arms

Published phase 2 data exist for both compounds and phase 3 programmes are running, so the literature is growing quickly in both directions. Neither is a licensed medicine in the UK, and both are sold here as research compounds.

> Products are sold as research compounds. This guide compares published pharmacology and is not a dosing protocol.

---

Sold for research use only. Not a licensed medicine. No dose is on the label.

Source: https://vyraxlabs.co.uk/guides/retatrutide-vs-tirzepatide
